1 / 47

Oral Hypoglycemic Update

Oral Hypoglycemic Update. Anita Schwartz, PharmD , BCPS August 8 th , 2012 For Lafayette Medical Education Foundation, Inc. . Conflicts. This speaker has no conflict of interest with regard to this presentation. . Objectives. Review diagnostic tests and treatment goals for diabetes

thanh
Télécharger la présentation

Oral Hypoglycemic Update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Oral Hypoglycemic Update Anita Schwartz, PharmD, BCPS August 8th, 2012 For Lafayette Medical Education Foundation, Inc.

  2. Conflicts • This speaker has no conflict of interest with regard to this presentation.

  3. Objectives • Review diagnostic tests and treatment goals for diabetes • List oral hypoglycemic agents currently on the market • Classify oral hypoglycemic agents based on their mechanism, onset, duration, and place in therapy • Describe pros and cons of the different oral hypoglycemic agents available • Summarize limitations and contraindications of oral hypoglycemic agents

  4. Pre-Assessment Questions • True or False: • A HgbA1C of 6.7% on two occasions is diagnostic of diabetes. • True or False: • Giving rapaglinide (Prandin®) with meals and glimepiride (Amaryl®) daily is a very good therapy option as it mimics basal bolus insulin. • True or False: • Rosiglitazone (Avandia®) can decrease LDL cholesterol and is a good option for patients with heart disease.

  5. Classification and Diagnosis

  6. Normal Carbohydrate Metabolism ↑ Glucose Glycogenolysis Gluconeogenesis Postprandial metabolism Counterregulatory Hormones: Glucagon Epinephrine Cortisol Growth Hormone Insulin Incretin Amylin Turns On Glucose  Glycogen AA  Protein FFA  TG Turns Off Fasting metabolism ↓Glucose

  7. Classification of Diabetes • Type 1 diabetes • β-cell destruction • Type 2 diabetes • Progressive insulin secretory defect • Other specific types of diabetes • Genetic defects in β-cell function, insulin action • Diseases of the exocrine pancreas • Drug- or chemical-induced • Gestational diabetes mellitus ADA. I. Classification and Diagnosis. Diabetes Care 2012;35(suppl 1):S11

  8. Testing for Diabetes in Asymptomatic Patients • Consider testing overweight/obese adults (BMI ≥25 kg/m2) with one or more additional risk factors • In those without risk factors, begin testing at age 45 years • If tests are normal • Repeat testing at least at 3-year intervals • Use A1C, FPG, or 2-h 75-g OGTT • In those with increased risk for future diabetes • Identify and, if appropriate, treat other CVD risk factors ADA. II. Testing in Asymptomatic Patients. Diabetes Care 2012;35(suppl 1):S13.

  9. Diagnostic Criteria Note: In the absence of unequivocal hyperglycemia, result(s) should be confirmed by repeat testing. ADA. I. Classification and Diagnosis. Diabetes Care 2012;35(suppl 1):S12. Table 2.

  10. Prevention, Prevention, Prevention! • Refer patients with IGT, IFG, or A1C 5.7–6.4% to ongoing support program • Target weight loss = 7% of total body weight • Minimum of 150 min/week of moderate physical activity • Follow-up counseling important for success • Based on cost-effectiveness of diabetes prevention, third-party payers should cover such programs • In those with pre-diabetes, monitor for development of diabetes annually ADA. IV. Prevention/Delay of Type 2 Diabetes. Diabetes Care 2012;35(suppl 1):S16

  11. Prevention, Prevention, Prevention! • Medications shown to delay progression of IGT/IFG to T2DM • Metformin (US DPP, NEJM 2002) • Acarbose (STOP-NIDDM, Lancet 2002) • Piaglitazone (ACT NOW, presentation 2008) • Consider metformin for prevention of type 2 diabetes if IGT, IFG, or A1C 5.7–6.4% • Especially for those with BMI >35 kg/m2, age <60 years, and women with prior GDM • None are FDA approved for Diabetes Prevention ADA. IV. Prevention/Delay of Type 2 Diabetes. Diabetes Care 2012;35(suppl 1):S16

  12. Testing

  13. A1c Monitoring • Twice Yearly in those who have stable glycemic control and no therapy changes • Quarterly in patients whose therapy has changed or who are not meeting glycemic goals • Use of point-of-care (POC) testing for A1c provides the opportunity for more timely treatment changes ADA. V. Diabetes Care. Diabetes Care 2012;35(suppl 1):S18.

  14. A1C Correlation ADA. V. Diabetes Care. Diabetes Care 2012;35(suppl 1):S18. Table 8.

  15. Easy A1c Correlation • NOTE: This is an estimate only • (A1C -2) x 30 • i.e. A1C= 7%; (7-2) x30 = 150mg/dL

  16. Goals

  17. Glycemic Recommendations *Individualize goals based on these values. †Postprandial glucose measurements should be made 1–2 h after the beginning of the meal, generally peak levels in patients with diabetes ADA. V. Diabetes Care. Diabetes Care 2012;35(suppl 1):S20. Table 9.

  18. Goals: A1c • Goal: <7% • Lowering A1c <7% has been shown to reduce microvascular complications and, if implemented soon after the diagnosis of diabetes, is associated with long-term reduction in macrovascular disease • More stringent goals (i.e. 6.5%)are reasonable in patients if it can be achieved without significant hypoglycemia or side effect • New diagnosis of diabetes, long life expectancy and no significant CVD • Less stringent goals (i.e. 8%) may be reasonable for those who have experienced severe hypoglycemia, limited life expectancy, advanced complications, or extensive comorbidities. ADA. V. Diabetes Care. Diabetes Care 2012;35(suppl 1):S18-19.

  19. Studies ACCORD TRIAL Primary Outcomes: nonfatal MI, nonfatal stroke, CVD ADVANCE Primary Outcomes: Microvascular and Macrovascular Complications HR=0.90 (0.78-1.04) HR=0.90 (0.82-0.98) Gerstein HC, et al, for the Action to Control Cardiovascular Risk in Diabetes Study Group.N Engl J Med 2008;358:2545-2559 Patel A, et al,. for the ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-2572

  20. Blood Pressure and Lipid Goals †Based on patient characteristics and response to therapy, higher or lower systolic blood pressure targets may be appropriate. ‡In individuals with overt CVD, a lower LDL cholesterol goal of <70 mg/dL (1.8 mmol/L), using a high dose of statin, is an option. ADA. VI. Prevention, Management of Complications. Diabetes Care 2012;35(suppl 1):S32. Table 11.

  21. Oral Hypoglycemic Treatment

  22. Type 2 Diabetes Recommendations • Metformin + lifestyle changes at diagnosis providing no contraindication • Medications are ALWAYS to be used in combination with healthy meal planning and regular physical activity (150 minutes per week) • If marked elevation of A1c /blood glucose and/or symptomatic consider insulin (+ or – other agents) from the outset • If noninsulin monotherapy at maximal tolerated dose does not achieve /maintain the A1c goal over 3–6 months, add a second oral agent, a GLP-1 receptor agonist, or insulin ADA. V. Diabetes Care. Diabetes Care 2012;35(suppl 1):S21

  23. Non-Insulin Hypoglycemic Agents Oral • Biguanides • Sulfonylureas • Meglitinides • Thiazolidinediones • Alpha Glucosidase inhibitors • Incretin Enhancers (DPP-IV inhibitors) • Resin binder Parenteral • Amylin analogs • Incretin mimetics

  24. Pharmacology - Biguanides ADA. V. Diabetes Care. Diabetes Care 2012;35(suppl 1):S22. Adapted with permission from Silvio Inzucchi, Yale University

  25. Pharmacology - Sulfonylureas ADA. V. Diabetes Care. Diabetes Care 2012;35(suppl 1):S22. Adapted with permission from Silvio Inzucchi, Yale University.

  26. Pharmacology – Meglitinides ADA. V. Diabetes Care. Diabetes Care 2012;35(suppl 1):S22. Adapted with permission from Silvio Inzucchi, Yale University.

  27. Pharmacology – Thiazolidinediones (TZD) ADA. V. Diabetes Care. Diabetes Care 2012;35(suppl 1):S22. Adapted with permission from Silvio Inzucchi, Yale University.

  28. Pharmacology – Thiazolidinediones (TZD) ADA. V. Diabetes Care. Diabetes Care 2012;35(suppl 1):S22. Adapted with permission from Silvio Inzucchi, Yale University.

  29. TZDs and the FDA • Rosiglitazone • Restricted by FDA – can only be used by patients currently benefiting from therapy or do not get adequate DM treatment from other agents and not willing to use pioglitazone • 1-800-AVANDIA • Pioglitazone • FDA alert – ongoing analysis of risk of bladder cancer (with prolonged use >12 months) Lexi-Drugs Online [Internet]. Hudson (OH) : Lexi-Comp, Inc. 1978-2012[cited 2012 August 1].

  30. Pharmacology – Alpha-Glucosidase Inhibiters ADA. V. Diabetes Care. Diabetes Care 2012;35(suppl 1):S22. Adapted with permission from Silvio Inzucchi, Yale University.

  31. Pharmacology – Incretin Enhancers ADA. V. Diabetes Care. Diabetes Care 2012;35(suppl 1):S23. Adapted with permission from Silvio Inzucchi, Yale University.

  32. Pharmacology – IncretinMimetics ADA. V. Diabetes Care. Diabetes Care 2012;35(suppl 1):S23. Adapted with permission from Silvio Inzucchi, Yale University.

  33. Pharmacology – Amylin Analog Lexi-Drugs Online [Internet]. Hudson (OH) : Lexi-Comp, Inc. 1978-2012[cited 2012 August 1].

  34. Pharmacology – Bile Acid Sequestrants ADA. V. Diabetes Care. Diabetes Care 2012;35(suppl 1):S23. Adapted with permission from Silvio Inzucchi, Yale University.

  35. Typical A1c Reductions Unger J et al. Postgrad Med 2010; 122: 145-57

  36. Fasting vs. Postprandial Effect

  37. Fasting vs. Postprandial Effect AACE/ACE Consensus Panel for Type 2 Diabetes. Endocrine Practice 2009; 25: 540-559

  38. Considerations When Selecting Therapy • How long has the patient had diabetes (duration of disease – preservation of β-cell function)? • Which blood glucose level is not at target (fasting, postprandial, or both)? • Patient preference for route of administration (oral, injection)? • The degree of A1c lowering effect required to achieve goal? • Side effect profile and the patients tolerability? • Co – existing conditions ( CVD, osteoporosis, obesity, etc)?

  39. Drug Pearls

  40. Other Therapies to Consider

  41. Antihypertensives • ACEi or ARBs • If ACEi is not tolerated secondary to cough may try ARB • If ACEi is not tolerated secondary to angioedema DO NOT TRY ARB • Multiple medications are often needed to obtain blood pressure goals ADA. VI. Prevention, Management of Complications. Diabetes Care 2012;35(suppl 1):S29

  42. Dyslipidemic Agents • Statin therapy should be added to lifestyle therapy, regardless of baseline lipid levels • with overt CVD • without CVD >40 years who have one or more other CVD risk factors • For patients at lower risk (without overt CVD, <40 years, etc.) • Consider statin therapy in addition to lifestyle therapy if LDL cholesterol remains >100 mg/dL • In those with multiple CVD risk factors ADA. VI. Prevention, Management of Complications. Diabetes Care 2012;35(suppl 1):S30-31

  43. Antiplatelet Agents – Primary Prevention • Consider aspirin therapy (75–162 mg/day) • In those with type 1 or type 2 diabetes at increased cardiovascular risk (10-year risk >10%) • Includes most men >50 years of age or women >60 years of age who have at least one additional major risk factor • Family history of CVD • Hypertension • Smoking • Dyslipidemia • Albuminuria ADA. VI. Prevention, Management of Complications. Diabetes Care 2012;35(suppl 1):S32.

  44. Antiplatelet Agents – Secondary Prevention • Use aspirin therapy (75–162 mg/day) • Secondary prevention strategy in those with diabetes with a history of CVD • For patients with CVD and documented aspirin allergy • Clopidogrel (75 mg/day) should be used • Combination therapy with ASA (75–162 mg/day) and clopidogrel (75 mg/day) • Reasonable for up to a year after an acute coronary syndrome ADA. VI. Prevention, Management of Complications. Diabetes Care 2012;35(suppl 1):S32.

  45. Coronary Heart Disease Treatment • To reduce risk of cardiovascular events in patients with known CVD use the following if not contraindicated: • ACE inhibitor • Aspirin • Statin therapy • In patients with a prior MI • Beta-blockers should be continued for at least 2 years after the event ADA. VI. Prevention, Management of Complications. Diabetes Care 2012;35(suppl 1):S33.

  46. QUESTIONS

More Related